Trend of A-share and Hong Kong stock innovative drug sector this week
In the fourth week of February 2022, a total of 16 stocks in the innovative drug sector in mainland and Hong Kong rose and 31 stocks fell. Among them, the top three gainers are Rongchang bio-b (+ 17.65%), Shanghai Junshi Biosciences Co.Ltd(688180) -u (+ 14.18%), Frontier Biotechnologies Inc(688221) -u (+ 11.54%). The top three declines were Chuangsheng group-B (- 11.68%), heyu-b (- 11.41%) and tengshengbo medicine-b (- 11.26%). This week, the A-share innovative drug sector fell 2.04%, underperforming the CSI 300 index by 1.67pp, and biomedicine rose 2.06%. In the past six months, A-share innovative drugs have fallen by 7.12%, underperforming the CSI 300 index by 4.46pp, and biomedicine has fallen by 21.12%. This week, the innovative medicine sector of Hong Kong stocks fell 4.22%, outperforming the Hang Seng Index by 6.41pp, and Hang Seng healthcare fell 1.22%. Over the past six months, innovative drugs in Hong Kong stocks have fallen by 17.81%, underperforming the Hang Seng Index by 11.43pp, and Hang Seng health care has fallen by 31.64%.
Progress of key innovative drugs in China
In February, a total of 6 new drugs were approved for marketing in China. This week, two drugs were approved for listing in China, and two innovative drugs were approved for new indications. Nmpa approved montmorillonite of yipusheng for the treatment of diarrhea. Upatinib is approved by nmpa for adults and adolescents aged 12 and over with moderate to severe atopic dermatitis suitable for systematic treatment. Dociliumab of Sanofi has been approved as a new indication for the treatment of moderate to severe atopic dermatitis in children and adults aged ≥ 6 to 12 years old who have poor control of topical prescription drugs or are not recommended to use topical prescription drugs. It can be used in combination with or without topical corticosteroids Haisco Pharmaceutical Group Co.Ltd(002653) of cyclophenol was approved as a new indication for the induction and maintenance of general anesthesia.
Progress of overseas key innovative drugs
In February, five new drugs were approved by FDA. No new drugs have been approved this week. In February, two new drugs were approved for marketing in Europe. This week, a new drug was approved as calcipotriol, the ointment of Leo pharmaceutical. In February, a new drug was approved for marketing in Japan.
This week’s special topic – research and development progress of PARP inhibitors
There are 89 PARP inhibitors on the global market & under research, including 6 on the market, 4 in phase III, 7 in phase II, 6 in phase I / II and 15 in phase I. There are 17 Listed & under research in China, of which 4 have been listed ( Jiangsu Hengrui Medicine Co.Ltd(600276) , MSD, zaiding medicine and Baiji Shenzhou), 3 are in phase III clinic (Johnson & Johnson, Pfizer, Shanghai Junshi Biosciences Co.Ltd(688180) ), 2 are in phase II clinic, 5 are in phase I clinic and 3 are in ind3. Among the listed PARP inhibitors, olaparil has the most approved indications, including fallopian tube cancer, ovarian cancer and peritoneal cancer (first-line maintenance treatment); Pancreatic cancer (maintenance treatment); Breast cancer (second line); Castration resistance to prostate cancer (second-line). In 2021, olapari’s sales reached US $3.34 billion (+ 33.4%), and the approval of multiple indications promoted the sustained and rapid growth of olapari.
Progress of global key innovative drug transactions this week
There were 8 key transactions in the world this week, and 6 key transactions with disclosed amount. Companies involved include Fuhong Hanlin and Getz Pharma, Tibet Duo Rui Pharmaceutical Co.Ltd(301075) and Henan University of traditional Chinese medicine, kiniksa pharmaceuticals and Huadong Medicine Co.Ltd(000963) , code biotechnology and Takeda pharmaceuticals, Taiwan Haoding biotechnology and Odeon therapeutics, Shan Dong Kexing Bioproducts Co.Ltd(688136) and Antai.
Risk warning: drug price reduction risk; The implementation progress of medical reform policy is lower than the expected risk; Risk of R & D failure.
